Shares of BioScrip Inc (NASDAQ:BIOS) have earned an average rating of “Buy” from the seven research firms that are currently covering the firm, MarketBeat.com reports. Two analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. The average 1-year target price among brokers that have updated their coverage on the stock in the last year is $3.56.
A number of analysts have weighed in on BIOS shares. SunTrust Banks restated a “buy” rating and set a $3.25 price objective on shares of BioScrip in a research note on Thursday, March 8th. BidaskClub lowered shares of BioScrip from a “buy” rating to a “hold” rating in a research note on Friday, March 9th. Craig Hallum reiterated a “buy” rating and issued a $3.50 price target on shares of BioScrip in a research note on Thursday, March 8th. Finally, Zacks Investment Research lowered shares of BioScrip from a “hold” rating to a “sell” rating in a research note on Tuesday, March 13th.
Several hedge funds have recently made changes to their positions in BIOS. Gotham Asset Management LLC bought a new stake in shares of BioScrip in the fourth quarter worth approximately $114,000. MetLife Investment Advisors LLC bought a new stake in shares of BioScrip in the fourth quarter worth approximately $174,000. Two Sigma Advisers LP grew its stake in shares of BioScrip by 100.4% in the fourth quarter. Two Sigma Advisers LP now owns 128,245 shares of the company’s stock worth $373,000 after acquiring an additional 64,238 shares during the period. Wells Fargo & Company MN grew its stake in shares of BioScrip by 34.4% in the fourth quarter. Wells Fargo & Company MN now owns 217,450 shares of the company’s stock worth $634,000 after acquiring an additional 55,636 shares during the period. Finally, Cambridge Investment Research Advisors Inc. bought a new stake in shares of BioScrip in the first quarter worth approximately $635,000. Hedge funds and other institutional investors own 85.46% of the company’s stock.
NASDAQ:BIOS traded up $0.01 on Friday, reaching $2.87. 37,270 shares of the stock traded hands, compared to its average volume of 533,652. The firm has a market cap of $367.22 million, a P/E ratio of -6.55 and a beta of 0.08. The company has a debt-to-equity ratio of -4.79, a quick ratio of 1.30 and a current ratio of 1.70. BioScrip has a 12 month low of $1.80 and a 12 month high of $3.39.
BioScrip (NASDAQ:BIOS) last released its quarterly earnings data on Thursday, May 10th. The company reported ($0.12) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.01). The business had revenue of $168.60 million for the quarter, compared to analyst estimates of $164.72 million. The business’s quarterly revenue was down 22.6% compared to the same quarter last year. During the same period in the prior year, the company posted ($0.18) EPS. equities research analysts predict that BioScrip will post -0.31 EPS for the current year.
BioScrip Company Profile
BioScrip, Inc provides infusion solutions in the United States. It engages in the preparation, delivery, administration, and clinical monitoring of pharmaceutical treatments that are administered to a patient through intravenous, subcutaneous, intramuscular, intra-spinal, and enteral methods. The company is primarily involved in the intravenous administration of medications to treat a range of acute and chronic conditions, such as infections, nutritional deficiencies, immunologic and neurologic disorders, cancer, pain, and palliative care.
Receive News & Ratings for BioScrip Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioScrip and related companies with MarketBeat.com's FREE daily email newsletter.